Fox Chase Researcher Receives Grant for Study of RNA, Telomerase and Implications for Disease
August 25th 2023A Fox Chase Cancer Center researcher has been awarded a $2.5 million grant from the National Institute of General Medical Sciences to investigate RNA structure and stability, work that has implications for cancer, Alzheimer’s, and other degenerative diseases and continues the Fox Chase legacy of basic research.
Analysis Helps Distinguish the Molecular Profile of Intraductal Carcinoma of the Prostate
July 31st 2023Benjamin Miron, MD, explains the purpose of studying the molecular profile of intraductal carcinoma of the prostate, expands on the potential prognostic and targetable alterations identified in patients with this histology, and discusses the planned cohort expansion and analysis of RNA signatures in this population.
Selecting Optimal Therapy for Advanced Non-Clear Cell RCC
Focusing their discussion on a real-world patient scenario, expert panelists discuss treatment options in the setting of advanced non-clear cell renal cell carcinoma.
Advanced Clear Cell RCC: AE Profile of First-Line Combination Therapies
Expert perspectives on the adverse event profiles of first-line combination therapies in the advanced clear cell renal cell carcinoma space.
Fox Chase’s Dr. Elizabeth Plimack Appointed Treasurer of American Society of Clinical Oncology
June 12th 2023Elizabeth Plimack, MD, MS, Deputy Director and professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, has been appointed Treasurer of the American Society of Clinical Oncology.
Latinx Patients Highlight Barriers to Tumor Genomic Profiling for Cancer
Latinx patients with cancer had a low rate of tumor genomic profiling, partially due to structural and cultural barriers, according to findings from a qualitative study presented during the 5th Annual Regional SPEECH Conference and Retreat.
Liver Cancer Awareness Higher in Individuals Who Receive HBV/HCV Screening
Individuals in Philadelphia and New York City who were screened for the common liver cancer risk factors hepatitis B virus or hepatitis C virus displayed a higher level of knowledge of liver cancer.
SPEECH Conference Highlights Multiplicity of Ongoing Efforts in Cancer Care Equity
Young investigators, fellows, and medical students recently gathered at the Temple University Lewis Katz School of Medicine in Philadelphia, Pennsylvania, to network and share exciting research aimed at addressing disparities in the dissemination of cancer care at the 5th Annual Regional Synergistic Partnership for Enhancing Equity in Cancer Health Conference and Retreat.